Age: 60Dementia Risk: 0%2030405060708090100Dementia risk growsexponentially with age
This is primarily due to a cumulative effect of various risk factors. As we grow older, there is a higher likelihood of accumulating genetic and environmental factors that contribute to age-related changes in brain structure and function, such as reduced neuron count and decreased cognitive reserve, significantly amplify the risk of developing dementia in older individuals. Confounders such as lifestyle, access to quality healthcare, and genetics, also contribute to our risk. But we can address it.

A New Strategy For Creating
Dementia Therapies

For decades large pharmaceutical companies have been focused almost entirely on a single strategy for creating drugs for dementia, removal of toxic proteins from brain cells that build up in the last decades of life.

This is a reactive strategy, waiting until dementia has progressed too far and damage is, in many cases, irreversible. This approach also treats all dementia like a single disease. Not all dementia is the same just like not all breast cancer is the same.

Therapeutic interventions need to begin earlier before irreversible damage to the brain occurs and be tailored to people’s individual biomarkers. By tracking people’s brain health and biomarkers earlier in life, we are making preventative therapies a reality.

Our drugs reverse brain aging itself, rather than the late stage toxic proteins that accumulate after damage has irreversibly progressed.

Our AI platform takes a personalized approach based on markers of brain aging to design therapeutics

Traditional method

Most dementia drugs target amyloid plaques, this has been only moderately effective and in some cases drugs have severe side effects. We instead target the program of brain aging.

Neuroage method

We identify genes from people whose brains are aging more slowly. We then design drugs to target the proteins produced by those genes to rejuvenate the brain and treat neurodegenerative diseases.

How We Work

The NeuroAge platform identifies novel drug targets that control the rate of brain aging using large longitudinal and postmortem human brain cohorts.

Platform Section Illustration


We leverage large longitudinal living and postmortem cohorts of human brain data with multi-omics.


We use AI and causal inference to identify the causal drivers of brain aging.


Not all dementia is the same. We tailor drugs for the genetic and molecular makeup of individuals by testing them for their risk factors.


We design novel drugs for our targets.


We validate our drugs in human neurons induced directly from fibroblasts, in brain organoids, and in animals.


We run human clinical trials for FDA approval of our drugs for dementia and other age-related neurodegenerative disorders.


We leverage our diagnostic as a biomarker for our clinical trials for faster FDA approval.